Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29568011 | 1.00 | NOS1 (0.52) | NOS1DHFRCA1CA2 | |
| SCHEMBL30311333 | 0.98 | NOS1 (0.54) | NOS1DHFRCA1CA2 | |
| SCHEMBL64019 | 0.98 | NOS1 (0.54) | NOS1DHFRCA1CA2 | |
| Bromide SCHEMBL29695408 | 0.97 | NOS1 (0.52) | NOS1DHFRCA1CA2 | |
| Bromide SCHEMBL62895 | 0.97 | NOS1 (0.52) | NOS1DHFRCA1CA2 | |
| Bromide SCHEMBL28586331 | 0.95 | NOS1 (0.51) | NOS1DHFRCA1CA2 | |
| SCHEMBL11327528 | 0.84 | PIK3CG (0.50) | NOS1CA1CA2 | |
| SCHEMBL31087253 | 0.84 | PIK3CG (0.50) | NOS1CA1CA2 | |
| Bromide SCHEMBL11634826 | 0.83 | DHFR (0.50) | DHFR | |
| Hydrochloric Acid SCHEMBL6448505 | 0.83 | NOS1 (0.52) | NOS1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4549472-A2 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG, LLC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4013374-B1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG LLC (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12163955-B2 | Antibodies to methotrexate and uses thereof | ARK DIAGNOSTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240319176-A1 | ANTIBODIES TO METHOTREXATE AND USES THEREOF | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2024-09-26 | — | — | US | disclosed |
| US-20220296485-A1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG, LLC | 2022-09-22 | — | — | US | disclosed |
| US-20220241429-A1 | Antifolate-Carrying Nanoparticles and Their Use in Medicine | MIDATECH LTD (GB) | 2022-08-04 | — | — | US | disclosed |
| EP-4013374-A1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG, LLC (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555038-A | Compositions and methods for sunscreen compounds | 普米戴格有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3893938-A1 | ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE | Midatech Ltd (GB) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021034834-A1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG, LLC (US) | 2021-02-25 | — | — | WO | disclosed |
| EP-2234998-A2 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | Tydock Pharma S.r.l. (IT) | 2010-10-06 | — | — | EP | disclosed |
| US-20100227798-A1 | USE OF THE STAUDINGER LIGATION IN IN VIVO ASSEMBLY OF A BIOLOGICALLY ACTIVE COMPOUND | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2010-09-09 | — | — | US | disclosed |
| WO-2009080367-A2 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCKPHARMA S.R.L. (IT) | 2009-07-02 | — | — | WO | disclosed |
| EP-2001512-A2 | USE OF THE STAUDINGER LIGATION IN IN VIVO ASSEMBLY OF A BIOLOGICALLY ACTIVE COMPOUND | Koninklijke Philips Electronics N.V. (NL) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110811-A2 | USE OF THE STAUDINGER LIGATION IN IN VIVO ASSEMBLY OF A BIOLOGICALLY ACTIVE COMPOUND | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2007-10-04 | — | — | WO | disclosed |
| US-20060035901-A1 | Methotrexate derivatives useful for treating cancer and arthritis | SERENEX, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| WO-2006014706-A2 | METHOTREXATE DERIVATIVES USEFUL FOR TREATING CANCER AND ARTHRITIS | SERENEX, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-0154173-B1 | PTERIDINE DERIVATIVES, AN ANTICANCER COMPOSITION CONTAINING SAME AND A PROCESS FOR THE PRODUCTION OF SAID DERIVATIVES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| US-4820706-A | Pteridine derivatives and method of treating leukemia employing same | RESEARCH CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0154173-A2 | Pteridine derivatives, an anticancer composition containing same and a process for the production of said derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240319176-A1 | ANTIBODIES TO METHOTREXATE AND USES THEREOF | MTX1, DHFR, MTX2 | CA2 3763/4885NOS1 3797/4885DHFR 2/4885 |
| US-20220296485-A1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | NQO1, XPA, ERCC1 | CA2 4032/4885NOS1 2219/4885DHFR 1243/4885 |
| US-12163955-B2 | Antibodies to methotrexate and uses thereof | MTX1, DHFR, MTX2 | CA2 3763/4885NOS1 3797/4885DHFR 2/4885 |
| US-20060035901-A1 | Methotrexate derivatives useful for treating cancer and arthritis | EGFR, ERBB2, MET | CA2 4231/4885NOS1 3913/4885DHFR 12/4885 |
| US-20220241429-A1 | Antifolate-Carrying Nanoparticles and Their Use in Medicine | FOLR1, FOLR2, SLC19A1 | CA2 748/4885NOS1 861/4885DHFR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.